A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?

Expert Opin Investig Drugs. 2020 Feb;29(2):103-106. doi: 10.1080/13543784.2020.1681397. Epub 2019 Oct 24.
No abstract available

Keywords: Canakinumab; diabetes; drug therapy; metabolic inflammation; nonalcoholic fatty liver disease.

Publication types

  • Editorial

MeSH terms

  • Animals
  • Humans
  • Interleukin-1alpha / antagonists & inhibitors*
  • Interleukin-1alpha / metabolism
  • Interleukin-1beta / antagonists & inhibitors*
  • Interleukin-1beta / metabolism
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / physiopathology

Substances

  • Interleukin-1alpha
  • Interleukin-1beta